Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review (abstract) Dr Yi Pan (author)

(case report/review) Conclusions Endometrioid ovarian carcinoma may benefit from aromatase inhibitors, especially when the tumour burden is low after primary chemotherapy or when the inhibitor is used as maintenance therapy between chemotherapies.